Marvel Biosciences Corp Total Assets
Marvel Biosciences Corp total assets. Based on the latest financial reports, Marvel Biosciences Corp (MRVL) holds total assets worth CA$683.06K CAD (≈ $494.11K USD) as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MRVL stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Marvel Biosciences Corp (2020–2025)
Total assets of Marvel Biosciences Corp from 2020 to 2025. This chart illustrates how Marvel Biosciences Corp's total assets have evolved over time, based on quarterly financial data. See Marvel Biosciences Corp stock price for real-time trading data and today's change.
Marvel Biosciences Corp - Asset Composition Analysis
Marvel Biosciences Corp Total Assets Breakdown (July 2025)
Marvel Biosciences Corp total assets breakdown as of July 2025. Marvel Biosciences Corp's total assets of CA$683.06K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 39.4% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Marvel Biosciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MRVL current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Marvel Biosciences Corp's current assets represent 100.0% of total assets in 2025, an increase from 99.9% in 2020.
- Cash Position: Cash and equivalents constituted 39.4% of total assets in 2025, down from 76.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Marvel Biosciences Corp Competitors by Total Assets
Key competitors of Marvel Biosciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Marvel Biosciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 0.14 | 2.02 |
| Quick Ratio | 0.16 | 0.14 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-3.65 Million | CA$-1.37 Million | CA$222.20K |
Marvel Biosciences Corp - Advanced Valuation Insights
This section examines the relationship between Marvel Biosciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 226.82 |
| Latest Market Cap to Assets Ratio | 15.41 |
| Asset Growth Rate (YoY) | -33.5% |
| Total Assets | CA$326.71K |
| Market Capitalization | $5.04 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Marvel Biosciences Corp's assets at a significant premium (15.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Marvel Biosciences Corp's assets decreased by 33.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Marvel Biosciences Corp (2020–2025)
The table below shows the annual total assets of Marvel Biosciences Corp from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | CA$326.71K ≈ $236.34K |
-33.50% |
| 2024-07-31 | CA$491.31K ≈ $355.41K |
-26.93% |
| 2023-07-31 | CA$672.39K ≈ $486.40K |
-26.40% |
| 2022-07-31 | CA$913.54K ≈ $660.84K |
-62.99% |
| 2021-07-31 | CA$2.47 Million ≈ $1.79 Million |
+733.87% |
| 2020-07-31 | CA$295.99K ≈ $214.11K |
-- |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more